×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AZN – astrazeneca plc - american depositary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AZN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
07:38 pm
azn
Why Astrazeneca (AZN) Outpaced the Stock Market Today [Yahoo! Finance]
Low
Report
Why Astrazeneca (AZN) Outpaced the Stock Market Today [Yahoo! Finance]
12/20
04:32 pm
azn
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows [Fortune]
Low
Report
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows [Fortune]
12/20
11:27 am
azn
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Neutral
Report
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
12/20
10:09 am
azn
8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030 [Yahoo! Finance]
Low
Report
8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030 [Yahoo! Finance]
12/20
09:22 am
azn
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza [Yahoo! Finance]
Low
Report
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza [Yahoo! Finance]
12/19
08:15 pm
azn
ATTENTION AZN SHAREHOLDERS: Investors who Lost Money on AstraZeneca PLC are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
Low
Report
ATTENTION AZN SHAREHOLDERS: Investors who Lost Money on AstraZeneca PLC are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
12/19
02:00 pm
azn
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
Low
Report
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
12/19
01:24 pm
azn
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman
Low
Report
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/16
10:05 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 16
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 16
12/5
06:01 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 05
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 05
12/4
09:02 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 04
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 04
12/2
10:36 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 02
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 02
12/2
10:28 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 02
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 02
11/25
06:54 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 25
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 25
11/20
11:15 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 20
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 20
11/18
06:11 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 18
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)]
8.3%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
TOP News Decliners
3/7
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News]
-4.1%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: